US FDA took an important step to advance policies for laboratory-developed tests services and next-generation sequencing with a Nov. 15 de novo classification of a tumor-profiling system.
The de novo in question was granted – with a class II, 510(k) risk designation – to MSK-IMPACT, a next-generation...